Shaily Engineering Plastics Limited share price
NSE: SHAILY · ISIN INE151G01028
Key numbers
- Market cap
- ₹ 14,453 Cr
- Current price
- ₹ 3,142.30
- 52-week high / low
- ₹ 3,615 / 1,771
- Stock P/E
- 82.1
- Book value
- ₹ 156.0
- Dividend yield
- 0.10%
- ROCE
- 29.3%
- ROE
- 26.9%
- Debt to equity
- 0.25
- Sales growth (3 yrs)
- 17.5%
- Profit growth (3 yrs)
- 69.1%
- 1-year return
- 35.4%
About Shaily Engineering Plastics Limited
Shaily Engineering Plastics Limited engages in the manufacture and sale of precision injection moulded plastic components/products in India. The company offers specialty devices, platform devices, inhalers, sprays and pumps, intricate insulin injector pens, auto-injectors, and specialty packaging and containers for solid and liquid formulations, as well as providing contract development and manufacturing services for the pharmaceutical industry. It also offers kitchen and cooking devices, as well as storage and cleaning products; and sheet steel furniture products, including cabinets, drawer units, tables, and storage units. In addition, the company provides plastic components for lighting, appliances, and automotive applications; and razors, pumps, sprays and packaging for the personal care market. It also exports its products to approximately 40 countries. Shaily Engineering Plastics Limited was incorporated in 1980 and is based in Vadodara, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 247 | 257 | 251 | 237 | 281 |
| Operating profit | 68 | 79 | 66 | 66 | 83 |
| Net profit | 41 | 51 | 37 | 40 | 48 |
| EPS (₹) | 8.95 | 11.15 | 8.13 | 8.74 | 10.44 |
Concall summary (2026-08-17)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- As committed earlier, our additional 25 million pen capacity is expected to become operational by end of September, taking our total installed pen injector capacity to approximately 75 million pens per annum.
- Machine utilization improved to 50.2% during Q1 F Y27 compared with 48.7% in Q1 FY26, reflecting a gradual improvement in capacity utilization.
Growth & demand
- Segment revenue grew 85% year-on-year to INR142 crores, contributing approximately 51% of consolidated revenue and becoming our largest business segment for the quarter.
- Healthcare revenue increased to INR142 crores from INR77 crores, representing an 85% year-on-year growth.
Margins & costs
- This led to volatility in key raw material prices, particularly polymers alongside logistic disruptions, container availability constraints and elevated freight costs.
- EBITDA stood at INR83 crores from INR70 crores, reflecting a growth of 18%, while EBITDA margin improved by 120 bps to 29.7%.
Capex & expansion
- I think we've said roughly 50%, 55% is kind of commitments and indication on that kind of that capacity.
- On Consumer Electronics, again, we have said that once we set up a plant down south, we would be looking at an investment of somewhere between INR80 crores to INR100 crores in that facility.
Risks & challenges
- The global operating environment remained challenging in the quarter with continued uncertainty arising from the geopolitical situation in West Asia and its wider impact on supply chain as well as commodity markets.
- Despite these external headwinds, we remain focused on execution.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.